DorsaVi bags UK deal
Medical device company DorsaVi (ASX:DVL) has bagged a third contract with the London Underground rail network as the operators of one of the world’s largest transport systems try to solve an OH&S riddle.
The ASX-listed outfit is responsible for “ViSafe” technology, which is a series of sensors which can be applied to workers to help analyse how they are moving throughout the day.
With the motion data captured, DVL is then able to generate insights into which actions could be causing stress to the body and which tasks could lead to injury.
The latest contract with Transport for London, operator of the London Underground, is for £100,000 ($A202,768).
It will apply the sensors to its workers to help figure out how to better work in a way which lessens the chances of workers getting musculoskeletal injuries.
In particular, Transport of London will be measuring stress to workers’ lower backs and shoulders while train drivers will be measured for the impact vibration of the train has on their muscles.
According to DVL, the UK Health and Safety Executive showed that 9.5 million working hours were lost in the 2015 financial year due to musculoskeletal injury, with manual handling work the main culprit.
More than half a million of these were injuries sustained in the workplace.
DVL is hoping its tech will allow employers to get a better idea of how their workers could potentially be injured while on the job, with the data to inform better work practices to lessen lost time due to injury.
“It’s great to see the transport sector embracing innovative technologies to reduce risk and improve productivity,” Zoe Whyatt from DorsaVi’s European office said.
“Wearable tech is dominating the health and leisure market and ViSafe has packaged powerful and highly sophisticated movement technology into miniature wireless sensors that allow data to be captured in the field in real time.”
About DorsaVi (ASX:DVL)
DorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications.
DorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.